Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Healthy
Interventions: TML-6 Granules, Placebo; Drug
Lead sponsor: Merry Life Biomedical Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
Interventions: HMPL-523; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Irvine, California • Georgetown, Delaware • Bethesda, Maryland + 7 more

Conditions: Multiple Sclerosis
Interventions: Tolebrutinib, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Hypertrophic Surgical Scar, Medical Adhesive Related Skin Injury
Interventions: SYLKE, Dermabond Prineo, Paper Tape; Device
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions: IDE892, IDE397; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more

Conditions: Healthy Volunteer
Interventions: PX-866; Drug
Lead sponsor: Cascadian Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Oncology, Quality of Life
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 15 Years to 39 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Chicago, Illinois • Winston-Salem, North Carolina

Conditions: Hypoglycemia
Interventions: XOMA 358 single dose level A, XOMA 358 single dose level B, XOMA 358 single dose level C, XOMA 358 multiple dose level 1; Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 5
States / cities: Aurora, Colorado • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Healthy
Interventions: PF-03382792 Cohort 1, PF-03382792 Cohort 2, PF-03382792, Food Effect cohort, CSF cohort; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Myeloid Leukemia
Interventions: Tagraxofusp, Venetoclax, Azacitidine; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 24
States / cities: Los Angeles, California • Stanford, California • Miami, Florida + 17 more

Conditions: Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF)
Interventions: 18F-BMS-986327; Diagnostic Test
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pyoderma Gangrenosum
Interventions: gevokizumab, Placebo, gevokizumab open-label; Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Oceanside, California • Tampa, Florida • Macon, Georgia + 4 more

Conditions: Sleep Disturbance, Sleep Disorder
Interventions: mHealth Stepped-care Intervention, Educational Control Condition, Questionnaire, Interview, Qualitative Interviews, Virtual Reality; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Alzheimer's Disease
Interventions: TB006, Placebo; Drug
Lead sponsor: TrueBinding, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Garden Grove, California • San Diego, California • Delray Beach, Florida + 10 more

Conditions: Aphasia, Stroke
Interventions: Magstim SuperRapid; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Advanced Hepatocellular Carcinoma
Interventions: Oprozomib, Sorafenib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Burlington, California • Denver, Colorado • Miami, Florida + 3 more

Conditions: Systemic Exposure to Sunscreen Ingredients
Interventions: Part 1: Cream, Part 1: Lotion, Part 1: Spray 1, Part 1: Spray 2, Part 2: Lotion, Part 2: Aerosol Spray, Part 2: Nonaerosol Spray, Part 2: Pump Spray; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Locally Advanced Sarcoma
Interventions: Dexamethasone, Doxorubicin, Fosaprepitant Dimeglumine, Ifosfamide, Laboratory Biomarker Analysis, Mesna, Ondansetron, Questionnaire Administration, Rolapitant Hydrochloride, Vincristine Sulfate; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non Small Cell Lung Cancer
Interventions: Radiation Therapy, Targeted TKI therapy; Device · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hepatic Impairment, Advanced Malignant Solid Tumor
Interventions: Tazemetostat; Drug
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 8
States / cities: Lake Mary, Florida • Chicago, Illinois • Royal Oak, Michigan + 5 more

Conditions: Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
Interventions: Valoctocogene roxaparvovec; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, EGFR Mutation-Related Tumors
Interventions: EMB-01, Osimertinib; Drug
Lead sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Orange, California • Boston, Massachusetts

Conditions: 3rd Line GIST
Interventions: ST571 + BYL719; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Other Cancer
Interventions: Enhancing Cancer Pain Management; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Phase 1 Safety and Tolerability Study of TML-6 in Healthy and Elderly Volunteers for Alzheimer's Disease Treatment

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants

Surgical Dressing Study Comparing SYLKE vs Other Common Incisional Dressings Following Abdominoplasty/Panniculectomy Patients

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers

Measuring Health Related Quality of Life in AYAs

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Improving Sleep in BMT Survivors

Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease

Post-Stroke Aphasia and Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment Study

Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Assessment of the Human Systemic Absorption of Sunscreen Ingredients

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

Development of an Intervention to Enhance Cancer Pain Management